Company Profile

Nabgen Inc
Profile last edited on: 10/5/21      CAGE: 8FCM6      UEI: JHTFFFJPHKL7

Business Identifier: Addressing issues involved in removing barriers to gene delivery
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

119 West Piedmont Avenue
Durham, NC 27707
   (919) 966-0905
Location: Single
Congr. District: 04
County: Durham

Public Profile

With strong ties to University of North Carolina Chapel Hill, NabGen Inc is structured around development of a novel strategy to block AAV neutralizing antibody activity. From successful clinical studies, a potentially huge market has been suggested for gene therapy with AAV vectors. However, for broader AAV vector application for patients, a major concernshas become the high prevalence of neutralizing antibody (Nab). The principals of NabGen are reported as having developed a vector independent protein-based strategy to universally block Nabs. The firm has initiated use of a unique mycoplasma derived protein and its analogues - designated Protein-M - whereby to enable successful gene delivery by preventing AAV neutralization of Nabs. Protein-M is able to interact with immunoglobulins from any species without antigen dependence by universally binding to variable regions on the antibody light and heavy chains.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NIH $300,000
Project Title: Novel Strategy to Block AAV Neutralizing Anitbody Activity
0 1 NIH $269,640
Project Title: Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction

Key People / Management

  Charles Askew -- President and Co-Founder

  Kaitlin Kiernan

  Chengwen Li

  Junjiang Sun

Company News

There are no news available.